News
Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...
6h
News Medical on MSNChinese study shows lasting weight loss after tirzepatide treatment
Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.
A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...
Explore more
Costa Rica: A recent systematic review published in the Cureus Journal of Medical Science has shed light on the potential of ...
GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...
A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...
11h
India Today on MSNWeight-loss drugs work, but here's when the weight starts to return
New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.
13h
Verywell Health on MSNIs This 5-Ingredient 'Japanese Mounjaro' Drink Worth Trying for Weight Loss?
Curious about the viral “Japanese Mounjaro” drink? Learn what it is, what it’s made of, and whether it can actually support ...
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results